FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006600283> ?p ?o ?g. }

• W2006600283 endingPage "581" @default.
• W2006600283 startingPage "575" @default.
• W2006600283 abstract "The aim of this study was to evaluate the efficacy and safety of the planned continuation of bevacizumab beyond first progression (BBP) in Japanese patients with metastatic colorectal cancer (mCRC). Previously untreated patients with assessable disease were treated with mFOLFOX6 plus bevacizumab until tumor progression, followed by FOLFIRI plus bevacizumab. The primary endpoint of the study was the second progression-free survival (2nd PFS), defined as duration from enrollment until progression after the second-line therapy. Secondary endpoints of the study were overall survival (OS), survival beyond first progression (SBP), progression-free survival (PFS), response rate (RR), disease control rate (DCR), and safety. In the first-line setting, 47 patients treated with mFOLFOX6 plus bevacizumab achieved RR of 61.7 %, DCR of 89.4 %, and median PFS of 13.1 months (95 % CI, 8.7–17.5 months). Thirty-one patients went on to receive a second-line therapy with FOLFIRI plus bevacizumab and achieved RR of 27.6 %, DCR of 62.1 %, and median PFS of 7.3 months (95 % CI, 5.0–9.6 months). Median 2nd PFS was 18.0 months (95 % CI, 13.7–22.3 months). The median OS and SBP were 30.8 months (95 % CI, 27.6–34.0 months) and 19.6 months (95 % CI, 13.5–25.7 months), respectively. No critical events associated with bevacizumab were observed during the second-line therapy. The planned continuation of bevacizumab during a second-line treatment, BBP strategy, is feasible for the Japanese mCRC patients." @default.
• W2006600283 created "2016-06-24" @default.
• W2006600283 creator A5005153787 @default.
• W2006600283 creator A5016704278 @default.
• W2006600283 creator A5018146056 @default.
• W2006600283 creator A5021947929 @default.
• W2006600283 creator A5022036602 @default.
• W2006600283 creator A5026008250 @default.
• W2006600283 creator A5039896704 @default.
• W2006600283 creator A5047606517 @default.
• W2006600283 creator A5048279225 @default.
• W2006600283 creator A5064746592 @default.
• W2006600283 creator A5064803578 @default.
• W2006600283 creator A5087008478 @default.
• W2006600283 creator A5087980449 @default.
• W2006600283 creator A5090672995 @default.
• W2006600283 date "2012-08-12" @default.
• W2006600283 modified "2023-09-27" @default.
• W2006600283 title "The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)" @default.
• W2006600283 cites W1970391226 @default.
• W2006600283 cites W1976558864 @default.
• W2006600283 cites W2092215947 @default.
• W2006600283 cites W2101711321 @default.
• W2006600283 cites W2123811123 @default.
• W2006600283 cites W2125447919 @default.
• W2006600283 cites W2133399075 @default.
• W2006600283 cites W2143743735 @default.
• W2006600283 cites W2157769714 @default.
• W2006600283 cites W2162313061 @default.
• W2006600283 cites W2162731664 @default.
• W2006600283 cites W2247454793 @default.
• W2006600283 cites W2314927739 @default.
• W2006600283 doi "https://doi.org/10.1007/s00280-012-1948-1" @default.
• W2006600283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3456942" @default.
• W2006600283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22886005" @default.
• W2006600283 hasPublicationYear "2012" @default.
• W2006600283 type Work @default.
• W2006600283 sameAs 2006600283 @default.
• W2006600283 citedByCount "12" @default.
• W2006600283 countsByYear W20066002832013 @default.
• W2006600283 countsByYear W20066002832014 @default.
• W2006600283 countsByYear W20066002832015 @default.
• W2006600283 countsByYear W20066002832016 @default.
• W2006600283 countsByYear W20066002832018 @default.
• W2006600283 countsByYear W20066002832019 @default.
• W2006600283 countsByYear W20066002832020 @default.
• W2006600283 countsByYear W20066002832021 @default.
• W2006600283 crossrefType "journal-article" @default.
• W2006600283 hasAuthorship W2006600283A5005153787 @default.
• W2006600283 hasAuthorship W2006600283A5016704278 @default.
• W2006600283 hasAuthorship W2006600283A5018146056 @default.
• W2006600283 hasAuthorship W2006600283A5021947929 @default.
• W2006600283 hasAuthorship W2006600283A5022036602 @default.
• W2006600283 hasAuthorship W2006600283A5026008250 @default.
• W2006600283 hasAuthorship W2006600283A5039896704 @default.
• W2006600283 hasAuthorship W2006600283A5047606517 @default.
• W2006600283 hasAuthorship W2006600283A5048279225 @default.
• W2006600283 hasAuthorship W2006600283A5064746592 @default.
• W2006600283 hasAuthorship W2006600283A5064803578 @default.
• W2006600283 hasAuthorship W2006600283A5087008478 @default.
• W2006600283 hasAuthorship W2006600283A5087980449 @default.
• W2006600283 hasAuthorship W2006600283A5090672995 @default.
• W2006600283 hasBestOaLocation W20066002831 @default.
• W2006600283 hasConcept C121608353 @default.
• W2006600283 hasConcept C126322002 @default.
• W2006600283 hasConcept C141071460 @default.
• W2006600283 hasConcept C143998085 @default.
• W2006600283 hasConcept C168563851 @default.
• W2006600283 hasConcept C203092338 @default.
• W2006600283 hasConcept C2776694085 @default.
• W2006600283 hasConcept C2776705615 @default.
• W2006600283 hasConcept C2777802072 @default.
• W2006600283 hasConcept C2780259306 @default.
• W2006600283 hasConcept C2780456651 @default.
• W2006600283 hasConcept C2780739268 @default.
• W2006600283 hasConcept C526805850 @default.
• W2006600283 hasConcept C71924100 @default.
• W2006600283 hasConceptScore W2006600283C121608353 @default.
• W2006600283 hasConceptScore W2006600283C126322002 @default.
• W2006600283 hasConceptScore W2006600283C141071460 @default.
• W2006600283 hasConceptScore W2006600283C143998085 @default.
• W2006600283 hasConceptScore W2006600283C168563851 @default.
• W2006600283 hasConceptScore W2006600283C203092338 @default.
• W2006600283 hasConceptScore W2006600283C2776694085 @default.
• W2006600283 hasConceptScore W2006600283C2776705615 @default.
• W2006600283 hasConceptScore W2006600283C2777802072 @default.
• W2006600283 hasConceptScore W2006600283C2780259306 @default.
• W2006600283 hasConceptScore W2006600283C2780456651 @default.
• W2006600283 hasConceptScore W2006600283C2780739268 @default.
• W2006600283 hasConceptScore W2006600283C526805850 @default.
• W2006600283 hasConceptScore W2006600283C71924100 @default.
• W2006600283 hasIssue "4" @default.
• W2006600283 hasLocation W20066002831 @default.
• W2006600283 hasLocation W20066002832 @default.
• W2006600283 hasLocation W20066002833 @default.
• W2006600283 hasLocation W20066002834 @default.
• W2006600283 hasOpenAccess W2006600283 @default.
• W2006600283 hasPrimaryLocation W20066002831 @default.

• next